Study aims to find new ways of alleviating the long-term effects of COVID-19 - News-Medical
Frankfurt University Hospital’s Department of Infectious Diseases is leading a study, RAPID_REVIVE, funded by the German Federal Ministry of Education and Research (BMBF), to treat post-COVID syndrome (PCS) with vidofludimus calcium. The phase 2, adaptive, randomized, placebo-controlled, and double-blind clinical trial aims to alleviate long-term COVID-19 effects like fatigue and cognitive impairment. The study, part of the German Network of University Medicine (NUM), will include 376 patients at eleven NAPKON locations and adjust treatment allocation based on interim evaluations.
Reference News
Frankfurt University Hospital’s Department of Infectious Diseases is leading a study, RAPID_REVIVE, funded by the German Federal Ministry of Education and Research (BMBF), to treat post-COVID syndrome (PCS) with vidofludimus calcium. The phase 2, adaptive, randomized, placebo-controlled, and double-blind clinical trial aims to alleviate long-term COVID-19 effects like fatigue and cognitive impairment. The study, part of the German Network of University Medicine (NUM), will include 376 patients at eleven NAPKON locations and adjust treatment allocation based on interim evaluations.